Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2016-10-28 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2016-10-28 English
FORM 3 -
Director's Dealing
2016-10-28 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 26, 2016. It includes two main items: Item 2.02, which reports results of operations and financial condition for the quarter ended September 30, 2016, and Item 5.02, which announces the appointment of a new director to the board. The document contains detailed information about the director appointment, including compensation and indemnification agreements, which fits the category of Board/Management Information. The financial results are mentioned as a press release and conference call, but the actual financial data is not included in this filing; it is furnished as an exhibit. Therefore, the primary classification is Board/Management Information (MANG). The document length (6002 characters) and content confirm it is not merely an announcement of a report but includes substantive management information about board changes.
2016-10-27 English
Regulatory Filings 2016
Regulatory Filings
2016-10-25 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from Innoviva, Inc. addressed to the SEC staff responding to comments on the company's previously filed Form 10-K for the fiscal year ended December 31, 2015, and a Form 8-K filed July 28, 2016. The letter discusses detailed accounting and disclosure issues related to the 10-K, including segment reporting, capitalized fees, and non-GAAP financial measures. It references specific accounting standards (ASC 280, ASC 350-30-50-1) and includes detailed responses to SEC staff comments. The document is not the 10-K report itself but a correspondence related to the SEC review process of the 10-K filing. It is a regulatory correspondence responding to SEC comments, which fits best under Regulatory Filings (RNS) as it does not contain the full annual report or financial statements but is a compliance and disclosure response letter.
2016-09-23 English
Regulatory Filings 2016
Regulatory Filings
2016-09-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.